Genmab A (GMAB) Non-Current Deferred Tax Liability (2024 - 2026)

Genmab A has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $365.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 10.61% year-over-year to $365.0 million; the trailing twelve-month figure through Mar 2026 stood at $365.0 million (up 10.61% YoY), and the FY2025 full-year result was $364.0 million, up 10.3% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $365.0 million, roughly flat from $364.0 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $365.0 million in Q1 2026, with the low at $330.0 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $341.5 million across 3 years, with a median of $330.0 million in 2024.
• Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability increased 10.3% — and 2026, when it advanced 10.61%.
• Genmab A's Non-Current Deferred Tax Liability stood at $330.0 million in 2024, then advanced by 10.3% to $364.0 million in 2025, then grew by 0.27% to $365.0 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $365.0 million (Q1 2026), $364.0 million (Q4 2025), and $330.0 million (Q3 2025), per Business Quant data.